
News|Articles|November 1, 2012
From the European Society for Medical Oncology 2012 Congress: Additional safety, tolerability data for tivozanib versus sorafenib in metastatic RCC shows fewer adverse events
New data demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first-line setting for patients with metastatic renal cell carcinoma (RCC), was presented at ESMO's 2012 Congress.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilar denosumab could save $0.59 per member per month
2
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
3
Racial differences in treatment priorities highlight opportunity to strengthen shared decision-making in lung cancer care
4
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
5






















































